My podcast journey led me to a woman who chose to not leave women with Metastatic Breast cancer behind. Upon reading her story, immersing myself in her blog and watching all her videos I knew I wanted to know more. What had led her to make this choice? What was her vision of what she hoped to do? How would she really impact the lives of these women?
Dr. Rebecca Timlin-Scalera was diagnosed with Stage 4 Metastatic Breast cancer when she was 43 years old. Moreover, according to the doctors, she had three years to live. With a 7-year old son and a 10-year old daughter, Rebecca feared for her kids and how they’d live without her.
Fortunately for her, a month after her diagnosis, she knows that her cancer is not in her bones. Moreover she is now at Stage 3 and could begin to seek a cure.
But what about all the women she’d met, who sat with her in the waiting rooms, who had Stage 4 cancer? What would happen to them? Could she support them to find a cure versus just extending their lives?
How did she really impact the lives of women?
Her choice to not leave these women behind led her to stop her neuropsychology practice. And put all her time and energy into her newly created Cancer Couch Foundation. Where her vision is to raise research funds specifically focused on a cure for metastatic breast cancer.
She’s using her medical background to choose the research studies she wants to fund. She’s putting the fun into her fundraising efforts and creating events that raise funds for both the Dana-Farber Cancer Institute in Boston and Memorial Sloan Kettering in New York.
She recently presented a $125,000 check to The Dana-Farber Cancer Institute, for which they’ve committed to match the funds. And, she’s off to do the same thing to Memorial Sloan Kettering.
She’s one woman who made one “small” choice, a choice that is now affecting so many.
To learn more about Rebecca’s efforts, the specifics of the ongoing research, and her fundraising opportunities, please visit her site.
To subscribe to the podcast on iTunes, visit this page.